Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.46 |
| ▸ | ERN1 | O75460 | 3/20 | 0.45 |
| ▸ | FYN | P06241 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | HCK | P08631 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1593440 | 0.84 | ALDH1A1 (0.59) | PDK2KEAP1NFE2L2ERN1FYN | |
| SCHEMBL1593436 | 0.81 | PDK2 (0.47) | PDK2KEAP1NFE2L2ERN1FYN | |
| SCHEMBL1593804 | 0.71 | ALDH1A1 (0.62) | PDK2ERN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1594138 | 0.71 | RAB9A (0.57) | PDK2KEAP1NFE2L2ERN1FYN | |
| SCHEMBL1595100 | 0.70 | USP30 (0.48) | PDK2KEAP1NFE2L2ERN1FYN | |
| SCHEMBL3876454 | 0.70 | CES2 (0.65) | ALDH1A1 | |
| SCHEMBL1594029 | 0.68 | HDAC4 (0.51) | PDK2ERN1ALDH1A1 | |
| SCHEMBL1594551 | 0.68 | EPHX2 (0.46) | PDK2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL1594389 | 0.68 | KEAP1 (0.45) | PDK2KEAP1NFE2L2ERN1FYN | |
| Trifluoroacetic Acid SCHEMBL5067780 | 0.68 | PDK2 (0.57) | PDK2KEAP1NFE2L2ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2465850-B1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2016-11-23 | — | — | EP | disclosed |
| US-8791137-B2 | Therapeutic compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2014-07-29 | — | — | US | disclosed |
| US-8791137-B2 | Therapeutic compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2014-07-29 | — | — | US | disclosed |
| US-8791137-B2 | Therapeutic compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2014-07-29 | — | — | US | disclosed |
| EP-1989185-B1 | THERAPEUTIC COMPOUNDS | HELICON THERAPEUTICS INC (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8399487-B2 | Pyrazole compounds and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-03-19 | — | — | US | disclosed |
| US-8399487-B2 | Pyrazole compounds and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-03-19 | — | — | US | disclosed |
| US-8399487-B2 | Pyrazole compounds and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-03-19 | — | — | US | disclosed |
| US-20110160248-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-06-30 | — | — | US | disclosed |
| US-20110160248-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-06-30 | — | — | US | disclosed |
| US-20110160248-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-06-30 | — | — | US | disclosed |
| US-7919626-B2 | Pyrazole compounds and uses thereof | HELICON THERAPEUTICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919626-B2 | Pyrazole compounds and uses thereof | HELICON THERAPEUTICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919626-B2 | Pyrazole compounds and uses thereof | HELICON THERAPEUTICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-12-16 | — | — | US | disclosed |
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-12-16 | — | — | US | disclosed |
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-12-16 | — | — | US | disclosed |
| US-20070203154-A1 | Therapeutic Compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
| US-20070203154-A1 | Therapeutic Compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
| US-20070203154-A1 | Therapeutic Compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | MAOB, MAOA, HTR1B | PDK2 1408/4885KEAP1 351/4885NFE2L2 1501/4885 |
| US-20110160248-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | MAOB, MAOA, HTR1B | PDK2 202/4885KEAP1 845/4885NFE2L2 2496/4885 |
| US-20070203154-A1 | Therapeutic Compounds | MAOB, MAOA, HTR1B | PDK2 1408/4885KEAP1 351/4885NFE2L2 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.